Regulation of the urokinase-type plasminogen activator gene by the oncogene Tpr-Met involves GRB2.
The oncogene Tpr-Met is a constitutively active form of the hepatocyte growth factor/scatter factor (HGF/SF) receptor Met. It comprises the intracellular moiety of Met linked to the dimerization domain of the nuclear envelope protein Tpr, thus functioning as a constitutively activated Met. HGF/SF is responsible for various biological processes including angiogenesis and wound healing, in which secreted serine protease urokinase-type plasminogen activator (uPA) is implicated. The action of HGF/SF on cells is mediated by the autophosphorylation of Met on two carboxyterminal tyrosine residues, Y1349VHVNATVY1356VNV. The two tyrosine residues provide docking sites for various effector molecules, suggesting that multiple signaling pathways are activated to exert biological effects of HGF/SF [Ponzetto et al., Cell (1994) 77: 261]. We found that Tpr-Met efficiently activates the uPA gene via a SOS/Ras/extracellular signal regulated kinase (ERK)-dependent signaling pathway. Mutation of Y1356, which abrogates GRB2 binding, reduced the induction to half of the control level, while mutation of Y1349 showed little effect on uPA induction, suggesting an important but partly replaceable role for GRB2 in Met-dependent uPA gene induction. Mutation of both Y1349VHV and Y1356VNV into optimal PI 3-kinase sites resulted in a residual induction of about one quarter of the control level, suggesting a potential role for PI 3-kinase. Dose-response analysis of the Tpr-Met showed a biphasic curve. These results suggest that the interplay among different signaling molecules on the receptor is important for full induction of the pathway leading to the activation of the uPA gene.
Besser
D
D
Friedrich Miescher Institute, Basel, Switzerland.
Bardelli
A
A
Didichenko
S
S
Thelen
M
M
Comoglio
P M
PM
Ponzetto
C
C
Nagamine
Y
Y
D016475:3T3 Cells / Q000201:enzymology / Q000378:metabolism / Q000502:physiology; D048868:Adaptor Proteins, Signal Transducing; D000818:Animals; D002478:Cells, Cultured; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004790:Enzyme Induction; D051380:GRB2 Adaptor Protein; D015971:Gene Expression Regulation, Enzymologic / Q000502:physiology*; D007668:Kidney / Q000166:cytology / Q000502:physiology; D008565:Membrane Proteins / Q000502:physiology; D051379:Mice; D020928:Mitogen-Activated Protein Kinases / Q000235:genetics / Q000502:physiology*; D009154:Mutation; D009419:Nerve Tissue Proteins / Q000502:physiology; D019869:Phosphatidylinositol 3-Kinases; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000502:physiology; D011401:Promoter Regions, Genetic; D017346:Protein Serine-Threonine Kinases / Q000502:physiology; D011506:Proteins / Q000502:physiology*; D011518:Proto-Oncogene Proteins / Q000502:physiology; D019859:Proto-Oncogene Proteins c-met; D019908:Proto-Oncogene Proteins c-raf; D015398:Signal Transduction / Q000502:physiology; D020664:Son of Sevenless Proteins; D015533:Transcriptional Activation; D014568:Urokinase-Type Plasminogen Activator / Q000096:biosynthesis / Q000235:genetics*; D018631:ras Proteins / Q000502:physiology
D048868:Adaptor Proteins, Signal Transducing; D051380:GRB2 Adaptor Protein; D008565:Membrane Proteins; D020928:Mitogen-Activated Protein Kinases; D009419:Nerve Tissue Proteins; D019869:Phosphatidylinositol 3-Kinases; D017853:Phosphotransferases (Alcohol Group Acceptor); D017346:Protein Serine-Threonine Kinases; D011506:Proteins; D011518:Proto-Oncogene Proteins; D019859:Proto-Oncogene Proteins c-met; D019908:Proto-Oncogene Proteins c-raf; D020664:Son of Sevenless Proteins; D014568:Urokinase-Type Plasminogen Activator; D018631:ras Proteins; C495949:Grb2 protein, mouse